Senseonics (SENS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
Annual meeting scheduled for May 20, 2026, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote on key proposals before the meeting date.
Voting matters and shareholder proposals
Election of three directors to serve until the 2029 annual meeting: Timothy T. Goodnow, Francine R. Kaufman, and Sharon Larkin.
Advisory vote on executive compensation (say-on-pay) and on the preferred frequency of future say-on-pay votes, with the board recommending annual votes.
Ratification of KPMG LLP as independent auditors for the fiscal year ending December 31, 2026.
Proposal to amend the certificate of incorporation to double authorized common stock from 70 million to 140 million shares.
Approval of the 2026 Equity Incentive Plan.
Board of directors and corporate governance
Board recommends all director nominees and all proposals for shareholder approval.
Latest events from Senseonics
- Record Q2 revenue and margin growth drive raised 2026 outlook and strong liquidity.SENS
Q2 2026 - Eversense 365 drives growth as pipeline advances toward fully implantable, invisible CGMs.SENS
Investor update - All six proposals, including director elections and share increase, were approved.SENS
AGM 2026 - Q1 2026 revenue rose 87% to $11.7M, with gross margin at 59% and net loss at $32.3M.SENS
Q1 2026 - Shareholders will vote on director elections, compensation, share increase, and a new equity plan.SENS
Proxy filing - Six key proposals, including share increase and new equity plan, recommended for approval.SENS
Proxy filing - Virtual meeting to vote on directors, compensation, share increase, and new equity plan.SENS
Proxy filing - 2025 revenue up 60% to $35.3M, with 65–76% growth expected in 2026.SENS
Q4 2025 - FDA launch of 365-day CGM spurs demand, but Q3 revenue drops and liquidity risks persist.SENS
Q3 2024